Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Erik Mittra; Amanda Abbott; Lisa Bodei

doi:10.2967/jnumed.120.258103

OtherHot Topics (Invitation Only)

Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Erik Mittra, Amanda Abbott and Lisa Bodei

Journal of Nuclear Medicine February 2021, jnumed.120.258103; DOI: https://doi.org/10.2967/jnumed.120.258103

Erik Mittra

1 OHSU, United States;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amanda Abbott

2 Society of Nuclear Medicine & Molecular Imaging;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lisa Bodei

3 Memorial Sloan Kettering Cancer Center, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Info & Metrics
PDF

This is a PDF-only article. The first page of the PDF of this article appears above.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 3

March 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Erik Mittra, Amanda Abbott, Lisa Bodei

Journal of Nuclear Medicine Feb 2021, jnumed.120.258103; DOI: 10.2967/jnumed.120.258103

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Erik Mittra, Amanda Abbott, Lisa Bodei

Journal of Nuclear Medicine Feb 2021, jnumed.120.258103; DOI: 10.2967/jnumed.120.258103

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Hot Topics (Invitation Only)

Hot Topic, Why will PET be the future of nuclear cardiology?
Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics

Show more Hot Topics (Invitation Only)

Clinical (Radionuclide Therapy)

Phase I trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients

Show more Clinical (Radionuclide Therapy)

Keywords

Oncology: General
Radionuclide Therapy
Research Methods
radioisotope therapy
radioligand therapy
radiopharmaceutical therapy

Main menu

User menu

Search

Landscape analysis of phase 2/3 clinical trials of targeted radionuclide therapy

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Hot Topics (Invitation Only)

Clinical (Radionuclide Therapy)

Similar Articles

Keywords